Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Real-World Impact of Prophylactic Pegfilgrastim in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Receiving Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With or Without Rituximab Chemotherapy in Korea

Conference Correspondent  - Conference Correspondent, ASHP

In this single-center, retrospective cohort study, electronic medical records were used to examine the real-world impact of prophylactic pegfilgrastim (PP) in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy.

The primary end point of this study was the comparison of febrile neutropenia and neutropenia events at first cycle. The secondary end point was the comparison of febrile neutropenia and neutropenia events across all cycles. Patients were randomized into 2 groups: the PP group and the non-PP group. Baseline characteristics were comparable across treatment groups.

A total of 160 patients were enrolled in this study at the Asan Medical Center in Korea. At cycle 1, the incidence of febrile neutropenia was significantly lower in patients who received PP versus patients who did not (6 PP cases [7.8%] vs 16 non-PP cases [19.3%]; P = 0.035). The rates of grades 3 and 4 neutropenia were significantly lower in the PP group (48.1%) versus patients who did not receive PP (67.5%; P = 0.013). There were statistically significant differences by cycle, but neutropenia incidence of the PP group trended.

Across all treatment cycles, the PP group reported lower incidence of grades 3 and 4 neutropenia but were only statistically significant at cycles 1 (P <0.05), 5 (P <0.01), and 6 (P <0.01). In a multiple logistic regression, hemoglobin <12 g/dL, platelets <100 k/mm3, and serum creatinine ≥1.4 mg/dL were associated with febrile neutropenia occurrence.

In conclusion, PP was associated with fewer neutropenic events in patients receiving CHOP with or without rituximab for DLBCL, regardless of cycles. The data report that it is reasonable to utilize PP during all chemotherapy cycles, especially cycle 1, as there is often a higher incidence of neutropenic events. Consideration should be given to patient-related risk factors when determining the appropriate use of pegfilgrastim.

Lee M. Abstract presented at ASHP Midyear Clinical Meeting. Las Vegas, NV; December 2016. Abstract 196544.

Related Items
A Look at SIRT Y-90 and the SARAH Trial
Valérie Vilgrain, MD
Videos published on May 11, 2017 in Conference Correspondent, Video, ILC
Nursing Implications of Chimeric Antigen Receptor T-Cell Therapy
Conference Correspondent  published on May 4, 2017 in Conference Correspondent, ONS
Neratinib After Trastuzumab-Based Adjuvant Therapy in Early-Stage HER2+ Breast Cancer: 5-Year Interim Analysis from the ExteNET Trial
Conference Correspondent  published on May 4, 2017 in Conference Correspondent, ONS
Alternative Dosing Schedules to Manage Adverse Events in Patients with Metastatic Renal-Cell Carcinoma Receiving Sunitinib
Conference Correspondent  published on May 4, 2017 in Conference Correspondent, ONS
Treatment-Related Adverse Events with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma in the Phase 2 CheckMate-205 Study
Conference Correspondent  published on May 4, 2017 in Conference Correspondent, ONS
Implication of Rituximab Priming Practices
Conference Correspondent  published on May 4, 2017 in Conference Correspondent, ONS
Standardization of Patient Assessments and Administration Guidelines for Blinatumomab
Conference Correspondent  published on May 4, 2017 in Conference Correspondent, ONS
What Is the Status of Immunotherapeutic Agents Playing a Role in the Treatment of SCLC, and How Should Oncology Nurses Educate and Prepare Patients?
Conference Correspondent  published on May 4, 2017 in Conference Correspondent, ONS
Turning on the Light Switch: Development and Implementation of an Immunotherapy Program for a Community-Based Oncology Practice
Conference Correspondent  published on May 4, 2017 in Conference Correspondent, ONS
Identifying and Treating Cytokine Release Syndrome
Conference Correspondent  published on May 3, 2017 in Conference Correspondent, ONS
Last modified: February 20, 2019